{
    "root": "597b4689-6d37-4cb8-b770-6a399eb44e5c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Amitiza",
    "value": "20250312",
    "ingredients": [
        {
            "name": "LUBIPROSTONE",
            "code": "7662KG2R6K"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "Amitiza is a chloride channel activator indicated for the treatment of: chronic idiopathic constipation (CIC) in adults. ( 1.1 ) opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.2 ) Limitations of Use: Effectiveness of Amitiza in the treatment of OIC in patients taking diphenylheptane opioids (e.g., methadone) has not been established. ( 1.2 , 7.1 ) irritable bowel syndrome with constipation (IBS-C) in women â‰¥ 18 years old. ( 1.3 )",
    "contraindications": "Recommended Dosage ( 2.1 ) CIC and OIC: 24 mcg twice daily. IBS-C: 8 mcg twice daily. See full prescribing information for dosage adjustment by indication and degree of hepatic impairment. Administration Instructions ( 2.2 ) Swallow capsules whole and do not break apart or chew, Take capsules with food and water, Assess periodically the need for continuous therapy.",
    "warningsAndPrecautions": "Amitiza is available as an oval, soft gelatin capsule containing 8 mcg or 24 mcg of lubiprostone with \"SPI\" printed on one side. Amitiza is available as follows:\n                  8 mcg pink capsule\n                  \n                     Bottles of 60 (NDC 23635-508-60)\n                  \n                  24 mcg orange capsule\n                  \n                     Bottles of 60 (NDC 23635-524-60)",
    "adverseReactions": "Amitiza is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction [see Warnings and Precautions (5.5)]."
}